Immunologic aspect of ovarian cancer and p53 as tumor antigen

Journal of Translational Medicine

Volumn 3, Issue , 2005, Pages

  Nijman, H W ^a   Lambeck, A ^a   van der Burg, S H ^b   van der Zee, A G J ^a   Daemen, T ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; PACLITAXEL; PLATINUM DERIVATIVE; POLYPEPTIDE; PROTEIN P53; TUMOR ANTIGEN;

CANARYPOX VIRUS; CANCER CHEMOTHERAPY; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; CPG ISLAND; CYTOREDUCTIVE SURGERY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PROTEIN FUNCTION; REVIEW; TUMOR CELL; VACCINIA VIRUS; VIRAL GENE DELIVERY SYSTEM;

EID: 27344432331     PISSN: 14795876     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-3-34     Document Type: Review

References (158)

1. Eisenkop SM, Spirtos NM: Procedures required to accomplish complete cytoreduction of ovarian cancer: is there a correlation with "biological aggressiveness" and survival? Gynecol Oncol 2001, 82:435-441.
2. Hoskins WJ, McGuire WP, Brady MF, Homesley HD, Creasman WT, Berman M, Ball H, Berek JS: The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 1994, 170:974-979.
3. Eisenkop SM, Friedman RL, Wang HJ: Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998, 69:103-108.
4. McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol 1998, 25:340-348.
5. Thigpen JT: Chemotherapy for advanced ovarian cancer: overview of randomized trials. Semin Oncol 2000, 27:11-16.
6. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D, Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 1998, 188:2357-2368.
7. Godfrey DI, Hammond KJ, Poulton LD, Smyth MJ, Baxter AG: NKT cells: facts, functions and fallacies. Immunol Today 2000, 21:573-583.
8. Sakaguchi S: Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000, 101:455-458.
9. Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH: Regulatory CD4(+)CD25(+) T cells in tumors from patients with early- stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001, 61:4766-4772.
10. Garza KM, Chan SM, Suri R, Nguyen LT, Odermatt B, Schoenberger SP, Ohashi PS: Role of antigen-presenting cells in mediating tolerance and autoimmunity. J Exp Med 2000, 191:2021-2027.
11. Smyth MJ, Godfrey DI, Trapani JA: A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol 2001, 2:293-299.
12. Zinkernagel RM, Ehl S, Aichele P, Oehen S, Kundig T, Hengartner H: Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunol Rev 1997, 156:199-209.
13. Bennett SR, Carbone FR, Karamalis F, Flavell RA, Miller JF, Heath WR: Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 1998, 393:478-480.
14. Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G: Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med 1996, 184:747-752.
15. Ridge JP, Di Rosa F, Matzinger P: A conditioned dendritic cell can be a temporal bridge between a CD4+ T- helper and a T-killer cell. Nature 1998, 393:474-478.
16. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ: T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 1998, 393:480-483.
17. Guerder S, Matzinger P: A fail-safe mechanism for maintaining self-tolerance. J Exp Med 1992, 176:553-564.
18. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, van der Voort EI, Rea D, Offringa R, Geuze HJ, Melief CJ et al.: Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 2000, 192:145-150.
19. Melief CJ, Toes RE, Medema JP, Van der Burg SH, Ossendorp F, Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 2000, 75:235-282.
20. Rosenberg SA: A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999, 10:281-287.
21. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S: Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003, 24:335-342.
22. Turtle CJ, Hart DN: Dendritic cells in tumor Immunology and immunotherapy. Curr Drug Targets 2004, 5:17-39.
23. Almand B, Resser JR, Lindman B, Nadaf S, Clark JI, Kwon ED, Carbone DP, Gabrilovich DI: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 2000, 6:1755-1766.
24. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001, 166:678-689.
25. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, Kavanaugh D, Carbone DP: Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat Med 1996, 2:1096-1103.
26. Kusmartsev S, Gabrilovich DI: Immature myeloid cells and cancer-associated immune suppression. Cancer Immunol Immunother 2002, 51:293-298.
27. Zou W, Machelon V, Coulomb-L'Hermin A, Borvak J, Nome F, Isaeva T, Wei S, Krzysiek R, Durand-Gasselinn I, Gordon A et al.: Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001, 7:1339-1346.
28. Eisenthal A, Polyvkin N, Bramante-Schreiber L, Misonznik F, Hassner A, Lifschitz-Mercer B: Expression of dendritic cells in ovarian tumors correlates with clinical outcome in patients with ovarian cancer. Hum Pathol 2001, 32:803-807.
29. Schlienger K, Chu CS, Woo EY, Rivers PM, Toll AJ, Hudson B, Maus MV, Riley JL, Choi Y, Coukos G et al.: TRANCE- and CD40 Ligand-matured Dendritic Cells reveal MHC class I restricted T cells specific for autologous tumor in late stage ovarian cancer patients. Clin Cancer Res 2003, 9:1517-1527.
30. Chu CS, Woo EY, Toll AJ, Rubin SC, June CH, Carroll RG, Schlienger K: Tumor-associated macrophages as a source of functional dendritic cells in ovarian cancer patients. Clin Immunol 2002, 102:291-301.
31. Loercher AE, Nash MA, Kavanagh JJ, Platsoucas CD, Freedman RS: Identification of an IL-10-producing HLA-DR-negative monocyte subset in the malignant ascites of patients with ovarian carcinoma that inhibits cytokine protein expression and proliferation of autologous T cells. J Immunol 1999, 163:6251-6260.
32. Curiel TJ, Wei S, Dong H, Alvarez X, Cheng P, Mottram P, Krzysiek R, Knutson KL, Daniel B, Zimmermann MC et al.: Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med 2003, 9:562-567.
33. Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
34. Dong H, Chen L: B7-H1 pathway and its role in the evasion of tumor immunity. J Mol Med 2003, 81:281-287.
35. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, Roche PC, Lu J, Zhu G, Tamada K et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
36. Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W et al.: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res 2003, 63:6501-6505.
37. Colonna M, Krug A, Cella M: Interferon-producing cells: on the front line in immune responses against pathogens. Curr Opin Immunol 2002, 14:373-379.
38. Salio M, Cella M, Vermi W, Facchetti F, Palmowski MJ, Smith CL, Shepherd D, Colonna M, Cerundolo V: Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol 2003, 33:1052-1062.
39. Curiel TJ, Cheng P, Mottram P, Alvarez X, Moons L, Evdemon-Hogan M, Wei S, Zou L, Kryczek I, Hoyle G et al.: Dendritic cell subsets differentially regulate angiogenesis in human ovarian cancer. Cancer Res 2004, 64:5535-5538.
40. Freedman RS, Tomasovic B, Templin S, Atkinson EN, Kudelka A, Edwards CL, Platsoucas CD: Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy. J Immunol Methods 1994, 167:145-160.
41. Freedman RS, Platsoucas CD: Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes. Cancer Treat Res 1996, 82:115-146.
42. Ioannides CG, Platsoucas CD, Rashed S, Wharton JT, Edwards CL, Freedman RS: Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites. Cancer Res 1991, 51:4257-4265.
43. Ioannides CG, Fisk B, Fan D, Biddison WE, Wharton JT, O'Brian CA: Cytotoxic T cells isolated from ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell Immunol 1993, 151:225-234.
44. Ioannides CG, Fisk B, Pollack MS, Frazier ML, Taylor WJ, Freedman RS: Cytotoxic T-cell clones isolated from ovarian tumour infiltrating lymphocytes recognize common determinants on non-ovarian tumour clones. Scand J Immunol 1993, 37:413-424.
45. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, Makrigiannakis A, Gray H, Schlienger K, Liebman MN et al.: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003, 348:203-213.
46. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, Evdemon-Hogan M, Conejo-Garcia JR, Zhang L, Burow M et al.: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.
47. Conejo-Garcia JR, Benencia F, Courreges MC; Gimotty PA, Khang E, Buckanovich RJ, Frauwirth KA, Zhang L, Katsaros D, Thompson CB et al.: Ovarian carcinoma expresses the NKG2D ligand Letal and promotes the survival and expansion of Cancer Res 2004, 64:2175-2182.
48. Conejo-Garcia JR, Buckanovich RJ, Benencia F, Courreges MC, Rubin SC, Carroll RG, Coukos G: Vascular Leukocytes Contribute to Tumor Vascularization. Blood 2004.
49. Conejo-Garcia JR, Benencia F, Courreges MC, Kang E, Mohamed-Hadley A, Buckanovich RJ, Holtz DO, Jenkins A, Na H, Zhang L et al.: Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med 2004, 10:950-958.
50. Nash MA, Ferrandina G, Gordinier M, Loercher A, Freedman RS: The role of cytokines in both the normal and malignant ovary. Endocr Relat Cancer 1999, 6:93-107.
51. Wang ZY, Gaggero A, Rubartelli A, Rosso O, Miotti S, Mezzanzanica D, Canevari S, Ferrini S: Expression of interleukin-18 in human ovarian carcinoma and normal ovarian epithelium: evidence for defective processing in tumor cells. Int J Cancer 2002, 98:873-878.
52. Chen H, Ye D, Me X, Chen B, Lu W: VEGF, VEGFRs expressions and activated STATs in ovarian epithelial carcinoma. Gynecol Oncol 2004, 94:630-635.
53. Huang M, Page C, Reynolds RK, Lin J: Constitutive activation of stat 3 oncogene product in human ovarian carcinoma cells. Gynecol Oncol 2000, 79:67-73.
54. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D et al.: Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 2004, 10:48-54.
55. Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS: HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2. Cell Immunol 1996, 174:116-128.
56. Nijman HW, van Diest PJ, Poort-Keesom RJ, Mensdorff-Pouilly S, Verstraeten RA, Kummer A, Meijer CJ, Melief CJ, Hilgers J, Kenemans P: T cell infiltration and MHC I and II expression in the presence of tumor antigens: An immunohistochemical study in patients with serous epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 2001, 94:114-120.
57. Ravenswaay Claasen HH, Fleuren GJ: The influence of combination chemotherapy on antigen expression in ovarian cancer. Gynecol Oncol 1995, 58:16-23.
58. Vitale M, Pelusi G, Taroni B, Gobbi G, Micheloni C, Rezzani R, Donato F, Wang X, Ferrone S: HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin Cancer Res 2005, 11:67-72.
59. Zaks TZ, Chappell DB, Rosenberg SA, Restifo NP: Fas-mediated suicide of tumor-reactive T cells following activation by specific tumor: selective rescue by caspase inhibition. J Immunol 1999, 162:3273-3279.
60. Offringa R, Van der Burg SH, Ossendorp F, Toes RE, Melief CJ: Design and evaluation of antigen-specific vaccination strategies against cancer. Curr Opin Immunol 2000, 12:576-582.
61. Van Den Eynde BJ, van der BP: T cell defined tumor antigens. Curr Opin Immunol 1997, 9:684-693.
62. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408:307-310.
63. Vousden KH, Lu X: Live or let die: the cell's response to p53. Nat Rev Cancer 2002, 2:594-604.
64. Vogelstein B, Kinzler KW: Cancer genes and the pathways they control. Nat Med 2004, 10:789-799.
65. Coukos G, Rubin SC: Chemotherapy resistance in ovarian cancer: new molecular perspectives. Obstet Gynecol 1998, 91:783-792.
66. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR: Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 2004, 303:1010-1014.
67. Greenblatt MS, Bennett WP, Hollstein M, Harris CC: Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res 1994, 54:4855-4878.
68. de Vries A, Florès ER, Miranda B, Hsieh HM, van Oostrom CT, Sage J, Jacks T: Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function. Proc Natl Acad Sci U S A 2002, 99:2948-2953.
69. Nijman HW, Kenemans P, Poort-Keesom RJ, Verstraeten RA, Mensdorff-Pouilly S, Verheijen RH, Melief CJ, Hilgers J, Meijer CJ: Influence of chemotherapy on the expression of p53, HER-2/neu and proliferation markers in ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999, 83:201-206.
70. Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ: The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996, 56:2178-2184.
71. Klemi PJ, Pylkkanen L, Kiilholma P, Kurvinen K, Joensuu H: p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma. Cancer 1995, 76:1201-1208.
72. Marks JR, Davidoff AM, Kerns BJ, Humphrey PA, Pence JC, Dodge RK, Clarke-Pearson DL, Iglehart JD, Bast RC, Jr., Berchuck A: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991, 51:2979-2984.
73. van der Zee AG, Hollema H, Suurmeijer AJ, Krans M, Sluiter WJ, Willemse PH, Aalders JG, de Vries EG: Value of P-glycoprotein, glutathione S-transferase pi, c-erbB-2, and p53 as prognostic factors in ovarian carcinomas. J Clin Oncol 1995, 13:70-78.
74. McCormick F: Cancer gene therapy: fringe or cutting edge? Nat Rev Cancer 2001, 1:130-141.
75. Snyder EL, Meade BR, Saenz CC, Dowdy SF: Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2004, 2:E36.
76. Offringa R, Vierboom MP, Van der Burg SH, Erdile L, Melief CJ: p53: a potential target antigen for immunotherapy of cancer. Ann N Y Acad Sci 2000, 910:223-233.
77. Voss RH, Lotz C, Cellary A, Theobald M: Targeting p53, hdm2, and CD19: vaccination and immunologic strategies. Bone Marrow Transplant 2000, 25 Suppl 2:S43-S45.
78. Hilburger RM, Abrams SI: Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol Immunother 2001, 49:603-612.
79. Yanuck M, Carbone DP, Pendleton CD, Tsukui T, Winter SF, Minna JD, Berzofsky JA: A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T-cells. Cancer Res 1993, 53:3257-3261.
80. Mathiassen S, Lauemoller SL, Ruhwald M, Claesson MH, Buus S: Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur J Immunol 2001, 31:1239-1246.
81. Mayordomo JI, Loftus DJ, Sakamoto H, De Cesare CM, Appasamy PM, Lotze MT, Storkus WJ, Appella E, DeLeo AB: Therapy of murine tumors with p53 wild-type and mutant sequence peptide- based vaccines. J Exp Med 1996, 183:1357-1365.
82. Noguchi Y, Chen YT, Old LJ: A mouse mutant p53 product recognized by CD4+ and CD8+ T cells. Proc Natl Acad Sci U S A 1994, 91:3171-3175.
83. Noguchi Y, Richards EC, Chen YT, Old LJ: Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci U S A 1995, 92:2219-2223.
84. Theobald M, Biggs J, Dittmer D, Levine AJ, Sherman LA: Targeting p53 as a general tumor antigen. Proc Natl Acad Sci U S A 1995, 92:11993-11997.
85. Vierboom MP, Nijman HW, Offringa R, van der Voort EI, van Hall T, van den BL, Fleuren GJ, Kenemans P, Kast WM, Melief CJ: Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. J Exp Med 1997, 186:695-704.
86. Peralta EA, Liu X, McCarthy TM, Wilson TG, Diamond DJ, Ellenhorn JD: Immunotherapy of bladder cancer targeting P53. J Urol 1999, 162:1806-1811.
87. Vierboom MP, Zwaveling S, Bos GMJ, Ooms M, Krietemeijer GM, Melief CJ, Offringa R: High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes. Cancer Res 2000, 60:5508-5513.
88. Ishida T, Chada, S, Stipanov M, Nadaf S, Ciemik FI, Gabrilovich DI, Carbone DP: Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses. Clin Exp Immunol 1999, 117:244-251.
89. Nikitina EY, Chada S, Muro-Cacho C, Fang B, Zhang R, Roth JA, Gabrilovich DI: An effective immunization and cancer treatment with activated dendritic cells transduced with full-length wild-type p53. Gene Ther 2002, 9:345-352.
90. Murakami T, Tokunaga N, Waku T, Gomi S, Kagawa S, Tanaka N, Fujiwara T: Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene. Clin Cancer Res 2004, 10:3871-3880.
91. Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I: Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53. Cancer Gene Ther 2001, 8:87-98.
92. Hurpin C, Rotarioa C, Bisceglia H, Chevalier M, Tartaglia J, Erdile L: The mode of presentation and route of administration are critical for the induction of immune responses to p53 and antitumor immunity. Vaccine 1998, 16:208-215.
93. Espenschied J, Lamont J, Longmate J, Pendas S, Wang Z, Diamond DJ, Ellenhorn JD: CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003, 170:3401-3407.
94. Krummel MF, Allison JP: CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med 1995, 182:459-465.
95. Hernandez J, Ko A, Sherman LA: CTLA-4 blockade enhances the CTL responses to the p53 self-tumor antigen. J Immunol 2001, 166:3908-3914.
96. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, Ellenhorn JD: Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004, 64:5407-5414.
97. Erdile LF, Smith D: CD40 activation enhances the magnitude of cellular immune responses against p53 but not the avidity of the effectors. Cancer Immunol Immunother 2000, 49:410-416.
98. Parajuli P, Pisarev V, Sublet J, Steffel A, Varney M, Singh R, LaFace D, Talmadge JE: Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell, response. Cancer Res 2001, 61:8227-8234.
99. Gnjatic S, Cai Z, Viguier M, Chouaib S, Guillet JG, Choppin J: Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol 1998, 160:328-333.
100. Sirianni N, Ha PK, Oelke M, Califano, J, Gooding W, Westra W, Whiteside TL, Koch WM, Schneck JP, DeLeo A et al.: Effect of human papillomavirus-16 infection on CD8+ T-cell recognition of a wild-type sequence p53264-272 peptide in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2004, 10:6929-6937.
101. Mitra R, Singh S, Khar A: Antitumour immune responses. Expert Rev Mol Med 2003, 2003:1-22.
102. Zwaveling S, Vierboom MP, Ferreira Mota SC, Hendriks JA, Ooms ME, Sutmuller RP, Franken KL, Nijman HW, Ossendorp F, Van der Burg SH et al.: Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 2002, 62:6187-6193.
103. Kuball J, Schmitz FW, Voss RH, Ferreira EA, Engel R, Guillaume P, Strand S, Romero P, Huber C, Sherman LA et al.: Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR. Immunity 2005, 22:117-129.
104. Mestas J, Hughes CC: Of mice and not men: differences between mouse and human immunology. J Immunol 2004, 172:2731-2738.
105. Cicinnati VR, Dworacki G, Albers A, Beckebaum S, Tuting T, Kaczmarek E, DeLeo AB: Impact of p53-based immunization on primary chemically-induced tumors. Int J Cancer 2005, 113:961-970.
106. Hoffmann TK, Nakano K, Elder EM, Dworacki G, Finkelstein SD, Appella E, Whiteside TL, DeLeo AB: Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants. J Immunol 2000, 165:5938-5944.
107. Houbiers JG, Nijman HW, Van der Burg SH, Drijfhout JW, Kenemans P, van de Velde CJ, Brand A, Momburg F, Kast WM, Melief CJ: In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53. Eur J Immunol 1993, 23:2072-2077.
108. Nijman HW, Houbiers JG, Van der Burg SH, Vierboom MP, Kenemans P, Kast WM, Melief CJ: Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J Immunother 1993, 14:121-126.
109. Nijman HW, Van der Burg SH, Vierboom MP, Houbiers JG, Kast WM, Melief CJ: p53, a potential target for tumor-directed T cells. Immunol Lett 1994, 40:171-178.
110. Nikitina EY, Clark JI, van Beynen J, Chada S, Virmani AK, Carbone DP, Gabrilovich DI: Dendritic cells transduced with full-length wild-type p53 generate antitumor cytotoxic T lymphocytes from peripheral blood of cancer patients. Clin Cancer Res 2001, 7:127-135.
111. Ropke M, Regner M, Claesson MH: T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand J Immunol 1995, 42:98-103.
112. Ropke M, Hald J, Guldberg P, Zeuthen J, Norgaard L, Fugger L, Svejgaard A, Van der BS, Nijman HW, Melief CJ et al.: Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc Nad Acad Sci U S A 1996, 93:14704-14707.
113. Theobald M, Biggs J, Hernandez J, Lustgarten J, Labadie C, Sherman LA: Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes. J Exp Med 1997, 185:833-841.
114. Umano Y, Tsunoda T, Tanaka H, Matsuda K, Yamaue H, Tanimura H: Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53. Br J Cancer 2001, 84:1052-1057.
115. Wurtzen PA, Pedersen LO, Poulsen HS, Claesson MH: Specific killing of P53 mutated tumor cell lines by a cross-reactive human HLA-A2-restricted P53-specific CTL line. Int J Cancer 2001, 93:855-861.
116. Asai T, Storkus WJ, Mueller-Berghaus J, Knapp W, DeLeo AB, Chikamatsu K, Whiteside TL: In vitro generated cytolytic T lymphocytes reactive against head and neck cancer recognize multiple epitopes presented by HLA-A2, including peptides derived from the p53 and MDM-2 proteins. Cancer Immun 2002, 2:3.
117. *4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003, 63:854-858.
118. McArdle SE, Rees RC, Mulcahy KA, Saba J, McIntyre CA, Murray AK: Induction of human cytotoxic T lymphocytes that preferentially recognise tumour cells bearing a conformational p53 mutant. Cancer Immunol Immunother 2000, 49:417-425.
119. Papadopoulos KP, Hesdorffer CS, Suciu-Foca N, Hibshoosh H, HanisPE: Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human breast carcinoma cells. Clin Cancer Res 1999, 5:2089-2093.
120. Petersen TR, Buus S, Brunak S, Nissen MH, Sherman LA, Claesson MH: Identification and design of p53-derived HLA-A2-binding peptides with increased CTL immunogenicity. Scand J Immunol 2001, 53:357-364.
121. Tokunaga N, Murakami T, Endo Y, Nishizaki M, Kagawa S, Tanaka N, Fujiwara T: Human monocyte-derived dendritic cells pulsed with wild-type p53 protein efficiently induce CTLs against p53 overexpressing human cancer cells. Clin Cancer Res 2005, 11:1312-1318.
122. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M et al.: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 1995, 25:1765-1769.
123. Van der Burg SH, de Cock K, Menon AG, Franken KL, Palmen M, Redeker A, Drijfhout J, Kuppen PJ, van d, V, Erdile L et al.: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 2001, 31:146-155.
124. Chikamatsu K, Albers A, Stanson J, Kwok WW, Appella E, Whiteside TL, DeLeo AB: P53(110-124)-specific human CD4+ T-helper cells enhance in vitro generation and antitumor function of tumor-reactive CD8+ T cells. Cancer Res 2003, 63:3675-3681.
125. Fujita H, Senju S, Yokomizo H, Saya H, Ogawa M, Matsushita S, Nishimura Y: Evidence that HLA class II-restricted human CD4+ T cells specific to p53 self peptides respond to p53 proteins of both wild and mutant forms. Eur J Immunol 1998, 28:305-316.
126. Angelopoulou K, Rosen B, Stratis M, Yu H, Solomou M, Diamandis EP: Circulating antibodies against p53 protein in patients with ovarian carcinoma. Correlation with clinicopathologic features and survival. Cancer 1996, 78:2146-2152.
127. Angelopoulou K, Diamandis EP: Detection of the TP53 tumour suppressor gene product and p53 auto-antibodies in the ascites of women with ovarian cancer. Eur J Cancer 1997, 33:115-121.
128. Crawford LV, Pim DC, Bulbrook RD: Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982, 30:403-408.
129. Gadducci A, Ferdeghini M, Buttitta F, Fanucchi A, Annicchiarico C, Prontera C, Bevilacqua G, Genazzani AR: Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer. Anticancer Res 1996, 16:3519-3523.
130. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Genazzani AR: Serum anti-p53 antibodies in the follow-up of patients with advanced ovarian carcinoma. Anticancer Res 1998, 18:3763-3765.
131. Gadducci A, Ferdeghini M, Buttitta F, Cosio S, Fanucchi A, Annicchiarico C, Gagetti O, Bevilacqua G, Genazzani AR: Assessment of the prognostic relevance of serum anti-p53 antibodies in epithelial ovarian cancer. Gynecol Oncol 1999, 72:76-81.
132. Labrecque S, Naor N, Thomson D, Matlashewski G: Analysis of the anti-p53 antibody response in cancer patients. Cancer Res 1993, 53:3468-3471.
133. Vennegoor CJ, Nijman HW, Drijfhout JW, Vernie L, Verstraeten RA, Mensdorff-Pouilly S, Hilgers J, Verheijen RH, Kast WM, Melief CJ et al.: Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 1997, 116:93-101.
134. Kuball J, Schuler M, Antunes FE, Herr W, Neumann M, Obenauer-Kutner L, Westreich L, Huber C, Wolfel T, Theobald M: Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man. Gene Ther 2002, 9:833-843.
135. Roth J, Dittmer D, Rea D, Tartaglia J, Paoletti E, Levine AJ: p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A 1996, 93:4781-4786.
136. Rosenwirth B, Kuhn EM, Heeney JL, Hurpin C, Tartaglia J, Bonnet MC, Moingeon P, Erdile L: Safety and immunogenicity of ALVAC wild-type human p53 (vCP207) by the intravenous route in rhesus macaques. Vaccine 2001, 19:1661-1670.
137. Menon AG, Kuppen PJ, Vander Burg SH, Offringa R, Bonnet MC, Harinck BI, Tollenaar RA, Redeker A, Putter H, Moingeon P et al.: Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients. Cancer Gene Ther 2003, 10:509-517.
138. Aarts WM, Schlom J, Hodge JW: Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity. Cancer Res 2002, 62:5770-5777.
139. Grosenbach DW, Barrientos JC, Schlom J, Hodge JW: Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res 2001, 61:4497-4505.
140. Kudo-Saito C, Schlom J, Hodge JW: Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses. Clin Cancer Res 2005, 11:2416-2426.
141. Marshall JL, Hoyer RJ, Toomey MA, Faraguna K, Chang P, Richmond E, Pedicano JE, Gehan E, Peck RA, Arlen P et al.: Phase I study in advanced cancer patients of a diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti-carcinoembryonic antigen immune responses. J Clin Oncol 2000, 18:3964-3973.
142. Marshall JL, Gulley JL, Arlen PM, Beetham PK, Tsang KY, Slack R, Hodge JW, Doren S, Grosenbach DW, Hwang J et al.: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005, 23:720-731.
143. Van der Burg SH, Menon AG, Redeker A, Franken KL, Drijfhout JW, Tollenaar RA, Hartgrink HH, van de Velde CJ, Kuppen PJ, Melief CJ et al.: Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors. Int J Cancer 2003, 107:425-433.
144. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, Whiteside TL: Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996, 68:276-284.
145. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH: Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother 2004, 53:633-641.
146. Abendstein B, Marth C, Muller-Holzner E, Widschwendter M, Daxenbichler G, Zeimet AG: Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer 2000, 88:1432-1437.
147. Vogl FD, Frey M, Kreienberg R, Runnebaum IB: Autoimmunity against p53 predicts invasive cancer with poor survival in patients with an ovarian mass. Br J Cancer 2000, 83:1338-1343.
148. Vogl FD, Stickeler E, Weyermann M, Kohler T, Grill HJ, Negri G, Kreienberg R, Runnebaum IB: p53 autoantibodies in patients with primary ovarian cancer are associated with higher age, advanced stage and a higher proportion of p53-positive tumor cells. Oncology 1999, 57:324-329.
149. Hogdall EV, Hogdall CK, Blaakaer J, Heegaard NH, Glud E, Christensen L, Bock JE, Norgaard-Pedersen B, Wiik A, Kjaer SK: P53 autoantibodies in sera from Danish ovarian cancer patients and their correlation with clinical data and prognosis. APMIS 2002, 110:545-553.
150. Mayerhofer K, Tempfer C, Kucera E, Hefler L, Zeisler H, Kainz C, Zeillinger R, Sliutz G: Humoral p53 antibody response is a prognostic parameter in ovarian cancer. Anticancer Res 1999, 19:875-878.
151. Marx D, Frey M, Zentgraf H, Adelssen G, Schauer A, Kuhn W, Meden H: Detection of serum autoantibodies to tumor suppressor gene p53 with a new enzyme-linked immunosorbent assay in patients with ovarian cancer. Cancer Detect Prev 2001, 25:117-122.
152. Numa F, Umayahara K, Suehiro Y, Hirakawa H, Nawata S, Suminami Y, Oga A, Ito T, Sasaki K, Kato H: Serum anti-p53 antibodies in uterine and ovarian cancer: association with dna sequence copy number abnormalities. Tumour Biol 2001, 22:162-168.
153. Montenarh M, Harlozinska A, Bar JK, Kartarius S, Gunther J, Sedlaczek P: p53 autoantibodies in the sera, cyst and ascitic fluids of patients with ovarian cancer. Int J Oncol 1998, 13:605-610.
154. Green JA, Robertson LJ, Campbell IR, Jenkins J: Expression of the p53 gene and presence of serum autoantibodies in ovarian cancer: correlation with differentiation. Cancer Detect Prev 1995, 19:151-155.
155. Barfoed AM, Petersen TR, Kirkin AF, Thor SP, Claesson MH, Zeuthen J: Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein. Scand J Immunol 2000, 51:128-133.
156. Eura M, Chikamatsu K, Katsura F, Obata A, Sobao Y, Takiguchi M, Song Y, Appella E, Whiteside TL, DeLeo AB: A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck. Clin Cancer Res 2000, 6:979-986.
157. Wurtzen PA, Claesson MH: A HLA-A2 restricted human CTL line recognizes a novel tumor cell expressed p53 epitope. Int J Cancer 2002, 99:568-572.
158. Rojas JM, McArdle SE, Horton RB, Bell M, Mian S, Li G, Ali SA, Rees RC: Peptide immunisation of HLA-DR-transgenic mice permits the identification of a novel HLA-DRbeta1*. Cancer Immunol Immunother 2005, 54:243-253.